Fighting respiratory diseases: Breathe life.


11.646 out of 50.000 euros

11.646 euros raised
Thanks to all!


Precipita in figures


Respiratory diseases are the leading cause of death and disability in the world. To investigate them, save lives.

The project
Who is behind

What is our goal?

Respiratory diseases affect hundred million people being the leading cause of death and disability in the world.  

Each year, 4 million people die prematurely from chronic respiratory disease and yet, health outcomes for lung disease have not improved in the last years to the same extent as cardiovascular disease and cancer.

Most of lung diseases do not have a cure and treatment guidelines aim to alleviate symptoms, to improve life quality and to reduce risk of death. An important problem is that these diseases are diagnosed late, when the disease is already established, decreasing the chances to cure them. Thus, the development of new methods to early detect the disease as well as looking for efficient treatments is critical.

Research in respiratory diseases is the hope for today and the promise for tomorrow. Research helps to the prevention, detection and treatment. Understanding the mechanisms of injury involved in the development of the disease will allow us to generate novel therapeutic strategies to revert or limit the pathological process. Moreover, studying the mechanisms of regeneration in the lung, will allow us to promote tissue repair integrating strategies to block disease progression together with therapies to recover functional tissue.

In our laboratory we study lung inflammation, fibrosis and regeneration to understand how the lung gets damaged and to identify therapies to inhibit the progression of the disease. In addition, we study the behavior of lung stem and progenitor cell populations that are in charge of the regeneration of damaged tissue to develop strategies promoting lung repair. 

Our major goal consists therefore in identifying cellular and molecular mechanisms involved in the development of respiratory diseases, specifically asthma, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), pulmonary hypertension and COVID-19, to find efficient therapies. In particular, based on our preliminary results, we propose:

  • To develop a tool for early detection of respiratory diseases (IPF, COPD, severe COVID-19) based on the presence of clonal hematopoiesis (accumulation of somatic mutations in hematopoietic cells in healthy individuals) as well as its role in the development of those diseases.
  • To evaluate the efficiency as anti-fibrotic therapy of newly identified molecular mechanisms in our laboratory in mouse models of lung fibrosis.
  • To extrapolate molecular mechanisms involved in mucous metaplasia found in mouse models to the human disease (asthma, COPD).
  • To identify novel mechanisms involved in pulmonary hypertension through the study of key celular interactions.
  • To study the mechanisms utilized by airway stem cells to maintain a functional immune ecosystem necessary for the initiation of the immune response.
  • To investigate the regenerative capacity of a newly identified cell type with a potentially relevant role in tissue repair post-injury.

To do that, we use different in vivo injury models to recapitulate the pathological processes of the specific disease and in vitro models using human cells isolated from lung biopsies by flow cytometry, as well as lung explants (Precision Cut Lung Slices) to test potential therapies for specific pathologies. Using the last available technologies of sequencing and imaging we aim to succeed in our goals.

Abaout Precipita
About us
Contact us
C/Pintor Murillo, 15
28100 Alcobendas (Madrid) - España
T.+(00 34) 91 425 09 09
A project from :Logo Ministerio
FECYT 2020. All right reserved
Legal terms | Privacy policy | Cookies policy
Powered by StockCrowd  Powered by StockCrowd
Información que debes conocer
Este sitio web utiliza cookies, para conocer nuestra política de cookies haga click aquí. Si estás de acuerdo con nuestra política de cookies haga click en el botón continuar.